Medical devices, healthcare technology and the business of care
PMA approval · P230009

Shield

Guardant Health, Inc. · Decision date Jul 26, 2024

FDA DECISIONP230009

What did the FDA approve?

FDA records P230009 as an original PMA application. The recorded decision is approval, dated Jul 26, 2024.

FDA approval order statement

The Shield test is a qualitative, in vitro diagnostic test intended to detect colorectal cancer derived alterations in cell-free DNA from blood collected in the Guardant Shield Blood Collection Kit. Shield is intended for colorectal cancer screening in individuals at average risk of the disease, age 45 years or older. Patients with a positive result should be followed by colonoscopy. Shield is not a replacement for diagnostic colonoscopy or for surveillance colonoscopy in high-risk individuals.
Regulatory pathway
Original PMA
Clinical specialty
Medical Genetics
Decision date
Jul 26, 2024

FDA source record

Regulatory record facts

Identifier
P230009
Regulatory pathway
Premarket approval application
Product code
PHP
Decision code
APPR
Decision date
Jul 26, 2024
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: System, colorectal neoplasia, DNA methylation and hemoglobin detection.

Product code
PHP
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P230009 received

    Application receipt date recorded by FDA.

  2. P230009 · FDA decision

    APPR

Timeline entries are records held by MedtechLedger for P230009. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P230009

Product / regulatory recordCompanyPathwayDecision dateSource
ShieldP230009/S020
Guardant Health, Inc.PMA supplementSep 16, 2026FDA
ShieldP230009/S021
Guardant Health, Inc.PMA supplementOct 5, 2026FDA

Explore the linked device profile

Other records with product code PHP

Product / regulatory recordCompanyPathwayDecision dateSource
SimpleScreen CRCP250029/S003
Freenome, LLCPMA supplementOct 27, 2026FDA
Freenome, LLCPMA approvalJul 24, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Guardant Health, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
3000 Hanover St., Palo Alto, CA, 94304

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records